JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell M2ntSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYjJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46OzJ|NjFOwG0> M4\BXXNCVkeHUh?=
H4 cell NVvuZ3dNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnrVTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwME[3NFch|ryP Mn\GV2FPT0WU
KGN cell M{DTPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkKwOUDPxE1? M1[zbHNCVkeHUh?=
786-0 cell NWH5U2h2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M37WPGlvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlczQTh7IN88US=> MonxV2FPT0WU
769-P cell NWnVSHM6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64NlIzPCEQvF2= M{XmenNCVkeHUh?=
K5 cell NWjw[3RDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXrpdHdxUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFE3OjRizszN NIPld5RUSU6JRWK=
MLMA cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEmwd4VKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODN{MUeg{txO NVPrZmJvW0GQR1XS
MLMA cell Mme3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvvTIpPUW6qaXLpeIlwdiCxZjDoeY1idiCPTF3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQDdyMzFOwG0> M3XvW3NCVkeHUh?=
EW-7 cell M{\BdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4HNRWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|I3QTVizszN NEPafGpUSU6JRWK=
SW1088 cell MlrmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFA3PTFizszN MlHZV2FPT0WU
MC-IXC cell MkXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnvGTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg4Pzl{IN88US=> MkTzV2FPT0WU
NCI-H2052 cell M3[1Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4r1fWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5yOEG1O{DPxE1? M4L0fnNCVkeHUh?=
IGR-1 cell NFK5Z49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHiSFgyUW6qaXLpeIlwdiCxZjDoeY1idiCLR2KtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTJyMkig{txO NGfO[3BUSU6JRWK=
DSH1 cell M3v6S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjJNnBKdmirYnn0bY9vKG:oIHj1cYFvKESVSEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1Ojl4IN88US=> M1vB[3NCVkeHUh?=
PA-1 cell MlnZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1O3V2lvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|AxPToQvF2= MWHTRW5ITVJ?
SK-MEL-3 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPSPWJKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5|MUKwO{DPxE1? M2XJeXNCVkeHUh?=
SW900 cell NFy3fYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\XO2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> Mn;FV2FPT0WU
CAKI-1 cell MoPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHXTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzPzN6IN88US=> NEPpdYtUSU6JRWK=
ES1 cell M37i[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7uPFVKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI5QTdizszN MnPxV2FPT0WU
SK-N-DZ cell M1;hVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlYzPTl3IN88US=> MkK2V2FPT0WU
RH-1 cell NYPaTmRWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmP3TY5pcWKrdHnvckBw\iCqdX3hckBTUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PFQ3OyEQvF2= M1zKbHNCVkeHUh?=
ES8 cell MmjSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3zuZWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PVcxOiEQvF2= MnXaV2FPT0WU
NEC8 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFzHT2RKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc3QTh{IN88US=> NV\3eYVbW0GQR1XS
LNCaP-Clone-FGC cell MkG1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFM2OzZizszN MlP5V2FPT0WU
HCE-4 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnm0TY5pcWKrdHnvckBw\iCqdX3hckBJS0VvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPVgxPyEQvF2= NIDiVWlUSU6JRWK=
U-118-MG cell NXWyUJBbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVfwS|FXUW6qaXLpeIlwdiCxZjDoeY1idiCXLUGxPE1OTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMEGwOlYh|ryP NUTSOpI3W0GQR1XS
GI-ME-N cell NWjw[mdiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7XflF4UW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1? MVnTRW5ITVJ?
LB1047-RCC cell Ml\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFv0W2VKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG2NVQ{KM7:TR?= MWHTRW5ITVJ?
HT-1080 cell NXfUUVJyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn3JTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yQTl{MTFOwG0> MmnpV2FPT0WU
NB69 cell Mnr1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXmfIJGUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{PTB2NzFOwG0> M3SwR3NCVkeHUh?=
NCI-H1693 cell NXGx[JB[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUPqdWJXUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3QTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0PFk2KM7:TR?= NGTwSYFUSU6JRWK=
HSC-3 cell M{XLS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYG0T2s1UW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDl7M{Og{txO MmH3V2FPT0WU
MDA-MB-231 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHYTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53NUi5PUDPxE1? NG\WfI9USU6JRWK=
HOS cell MmnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1zIb2lvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PFY{KM7:TR?= MoXjV2FPT0WU
BT-549 cell Mnv1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFm0N21KdmirYnn0bY9vKG:oIHj1cYFvKEKWLUW0PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzh6NzFOwG0> M3ryTXNCVkeHUh?=
NB17 cell M1vFTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVLiVYxuUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0> NGCwOnpUSU6JRWK=
5637 cell NFvGOYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXLJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke5OlUzKM7:TR?= NWfqRWFrW0GQR1XS
OVCAR-8 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3JTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OjR|NjFOwG0> MYrTRW5ITVJ?
G-402 cell NHPBTWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTQPW1MUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTNyM{Wg{txO M2fHXHNCVkeHUh?=
BB30-HNC cell MnnoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnLxTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO NF7NW4NUSU6JRWK=
HCC1806 cell NHrHN41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1PNPGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUiwOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODh|M{mg{txO Mk\kV2FPT0WU
COLO-800 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnNeIlKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5zMk[0JO69VQ>? NGXpOXJUSU6JRWK=
FADU cell MlTES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUX3N|l6UW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PjV3NzFOwG0> NUDzeIpYW0GQR1XS
NCI-H1651 cell M{DEd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGLJXmNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwM{m0NFkh|ryP NHjVbJlUSU6JRWK=
AGS cell M2DsPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEe3NVEh|ryP NFLXVHFUSU6JRWK=
CHP-212 cell MlPYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6PDB7IN88US=> NVj5W3k5W0GQR1XS
YAPC cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33EemlvcGmkaYTpc44hd2ZiaIXtZY4hYUGSQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFc4OTFizszN NFLwZYRUSU6JRWK=
GOTO cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnSzTY5pcWKrdHnvckBw\iCqdX3hckBIV1SRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60PVU4PiEQvF2= M2r6SXNCVkeHUh?=
KYSE-510 cell NHzzOVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OTFizszN MWDTRW5ITVJ?
NCI-H2342 cell NHTCe49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWDJPXBuUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNlc5KM7:TR?= NX7EfYpOW0GQR1XS
BFTC-905 cell NVOyUm9kT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVvJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh|NTFOwG0> MX\TRW5ITVJ?
EW-16 cell M1nHbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HmemlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlczODl|IN88US=> MlzhV2FPT0WU
SK-MEL-30 cell MoHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGHBRZFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{S1OFMh|ryP M3vwcnNCVkeHUh?=
HLE cell NY\IOVNYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHfNbIRKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|c1QDlizszN M3\iTHNCVkeHUh?=
T98G cell NF7sfmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHhTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63PVY{PSEQvF2= M4PJdHNCVkeHUh?=
HUTU-80 cell MnKyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1LnXmlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDR{Mkig{txO NGjMcIRUSU6JRWK=
NOS-1 cell NEPURmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{PBbGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk1PzZ4IN88US=> NF7MOpVUSU6JRWK=
SW780 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;EZWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=> NV63dnBJW0GQR1XS
KYSE-180 cell M2fydGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\HZWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl5NkW0JO69VQ>? MnfuV2FPT0WU
MDA-MB-361 cell NGDVToNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWX5TpZTUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65PFY1PyEQvF2= M4HJOHNCVkeHUh?=
SNU-C2B cell MoPRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2LWOmlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLVOyRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvODFzM{ig{txO NGLuZZdUSU6JRWK=
NCI-H661 cell NF[zdXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkTQTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvODZ7NDFOwG0> MVzTRW5ITVJ?
OE33 cell NWLQdYdLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHnxZpNKdmirYnn0bY9vKG:oIHj1cYFvKE:HM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE1Ozh7IN88US=> NXHPdnM{W0GQR1XS
TYK-nu cell M4rlRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFrVWnNKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjF6NkOg{txO M{P5b3NCVkeHUh?=
COLO-792 cell Mlf2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlrITY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjV{MUmg{txO NWDPNHY3W0GQR1XS
HEL cell MlHrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPXR|hJUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlI3PzZizszN NIT5dHlUSU6JRWK=
D-566MG cell NGjlcWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXH4[28zUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|M{S5NUDPxE1? NV\ET|J5W0GQR1XS
U031 cell NFTtd2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4rWXWlvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFE5OTZizszN MU\TRW5ITVJ?
COR-L23 cell MmWyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlzmTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzN2NjFOwG0> MXjTRW5ITVJ?
NCI-H2452 cell NVrRd4V2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkS1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPTJ{OEGg{txO M3zvOHNCVkeHUh?=
BB65-RCC cell NVnnTpBET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUGzU2tWUW6qaXLpeIlwdiCxZjDoeY1idiCEQk[1MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNkS1PUDPxE1? M3G3[XNCVkeHUh?=
CAL-33 cell M{n5Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoraTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PjZ3IN88US=> M4exd3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development, L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID